XML 39 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 30, 2013
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Sep. 18, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenue   $ 46,333     $ 40,134     $ 152,877 $ 120,614    
Deferred Revenue   28,858           28,858   $ 12,740  
Drug product revenue recognized   46,333     40,134     152,877 120,614    
Product [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenue   46,210     29,390     126,391 77,439    
Drug product revenue recognized   46,210     29,390     126,391 77,439    
Drug Product Revenue, Net [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenue   (262)     1,320     24,954 17,701    
Drug product revenue recognized   (262)     1,320     24,954 17,701    
Drug Product Revenue, Net [Member] | API Shipment [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenue   1,400 $ 400 $ 2,200 700 $ 600          
Drug product revenue recognized   1,400 $ 400 $ 2,200 700 600          
Japan [Member] | Drug Product Revenue, Net [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenue           14,400 $ 1,700        
Drug product revenue recognized           $ 14,400 $ 1,700        
AstraZeneca Agreements [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Recognized as Revenue               115,339      
AstraZeneca Agreements [Member] | U.S./RoW [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Aggregate considerations received               439,000      
AstraZeneca Agreements [Member] | China [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Upfront, non-contingent, non-refundable and time-based payments $ 376,700                    
Aggregate considerations received               77,200      
Transaction price and allocated to performance obligations                     $ 4,000
Contract asset   4,000           4,000      
Direct Sales [Member] | Product [Member]                      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                      
Total revenue   3,989     2,927     11,052 9,092    
Drug product revenue recognized   $ 3,989     $ 2,927     $ 11,052 $ 9,092